LT2890680T - N-(3-fluorbenzil-2-(5-(4-morfolinofenil)piridin-2-il)acetamidas, kaip proteintirozinkinazės moduliatorius - Google Patents

N-(3-fluorbenzil-2-(5-(4-morfolinofenil)piridin-2-il)acetamidas, kaip proteintirozinkinazės moduliatorius

Info

Publication number
LT2890680T
LT2890680T LTEP13760222.3T LT13760222T LT2890680T LT 2890680 T LT2890680 T LT 2890680T LT 13760222 T LT13760222 T LT 13760222T LT 2890680 T LT2890680 T LT 2890680T
Authority
LT
Lithuania
Prior art keywords
morpholinophenyl
fluorobenzyl
pyridin
acetamide
tyrosine kinase
Prior art date
Application number
LTEP13760222.3T
Other languages
English (en)
Inventor
David Hangauer
Original Assignee
Athenex, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athenex, Inc. filed Critical Athenex, Inc.
Publication of LT2890680T publication Critical patent/LT2890680T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LTEP13760222.3T 2012-08-30 2013-08-30 N-(3-fluorbenzil-2-(5-(4-morfolinofenil)piridin-2-il)acetamidas, kaip proteintirozinkinazės moduliatorius LT2890680T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695100P 2012-08-30 2012-08-30
US201361779868P 2013-03-13 2013-03-13
PCT/US2013/057565 WO2014036426A1 (en) 2012-08-30 2013-08-30 N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl)pyridin-2-yl) acetamide as protein|tyrosine kinase modulators

Publications (1)

Publication Number Publication Date
LT2890680T true LT2890680T (lt) 2018-05-10

Family

ID=49162280

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13760222.3T LT2890680T (lt) 2012-08-30 2013-08-30 N-(3-fluorbenzil-2-(5-(4-morfolinofenil)piridin-2-il)acetamidas, kaip proteintirozinkinazės moduliatorius

Country Status (12)

Country Link
US (5) US9926273B2 (lt)
EP (1) EP2890680B1 (lt)
JP (3) JP6499076B2 (lt)
KR (1) KR102346033B1 (lt)
CN (2) CN109999040A (lt)
CA (1) CA2883144C (lt)
ES (1) ES2664332T3 (lt)
HU (1) HUE037637T2 (lt)
LT (1) LT2890680T (lt)
SI (1) SI2890680T1 (lt)
TW (1) TWI664167B (lt)
WO (1) WO2014036426A1 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US9926273B2 (en) 2012-08-30 2018-03-27 Athenex, Inc. Composition and methods for modulating a kinase cascade
CN106902358B (zh) * 2015-12-21 2020-07-10 广州市香雪制药股份有限公司 口服制剂及其制备方法
CN106902357B (zh) * 2015-12-21 2021-08-03 广州市香雪制药股份有限公司 药物组合物及其应用、药物包合物、静脉制剂及制备方法
CN114516832B (zh) * 2020-11-20 2023-11-28 成都贝诺科成生物科技有限公司 一种微管蛋白抑制剂及其制备方法与应用
CN113354575B (zh) * 2021-06-07 2022-09-27 河南应用技术职业学院 一种特班布林的合成方法
CN115477608B (zh) * 2021-06-16 2023-12-12 成都贝诺科成生物科技有限公司 一种微管蛋白抑制剂及其制备方法与应用
WO2023134753A1 (zh) * 2022-01-14 2023-07-20 武汉人福创新药物研发中心有限公司 微管蛋白-src双靶点抑制剂

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1121922A (en) 1966-06-17 1968-07-31 Ici Ltd Pyrimidine derivatives
GB1147068A (en) 1966-12-02 1969-04-02 Ici Ltd Phenyl-pyridine derivatives
US3761477A (en) 1968-11-08 1973-09-25 Mc Neil Labor Inc Pyrazineacetic acids, lower alkyl esters, amides and salts
IT1044222B (it) 1972-05-23 1980-03-20 Zambeletti Spa L Bifenilil alcanoilaminopiridine ad attivita anti infiammatoria di lunga durata
AT341512B (de) 1975-01-09 1978-02-10 Thomae Gmbh Dr K Verfahren zur herstellung von neuen biphenylathern
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA1261835A (en) 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
JPS62252755A (ja) 1986-04-11 1987-11-04 Daikin Ind Ltd 新規ｎ−ベンジルベンズアミド誘導体およびこれを有効成分として含有する除草剤
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
US5232948A (en) 1990-09-10 1993-08-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted monocyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
CH685875A5 (fr) 1991-04-26 1995-10-31 Pierre Baudet Les N-phényl-benzamides protecteurs contre les effets nocifs de la lumière ultra-violette
WO1992020645A1 (en) 1991-05-20 1992-11-26 Tsumura & Co. Phellodendrine analogs and allergy type iv suppressor containing the same as active ingredient
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
DE4236103A1 (de) 1992-10-26 1994-04-28 Hoechst Ag Verfahren zur Kreuzkupplung von aromatischen Boronsäuren mit aromatischen Halogenverbindungen oder Perfluoralkylsulfonaten
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
FR2705671B1 (fr) 1993-05-26 1995-07-07 Inst Nat Sante Rech Med Nouveaux dérivés de l'hydroxybiphényle, leur préparation et les compositions pharmaceutiques qui les contiennent.
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5616344A (en) 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
FR2737721B1 (fr) 1995-08-08 1997-09-05 Roussel Uclaf Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant
WO1998021185A1 (en) 1996-11-08 1998-05-22 Sankyo Company, Limited Arylureas or arylmethylcarbamoyl derivatives
ES2318869T3 (es) 1997-02-20 2009-05-01 Massachusetts Institute Of Technology Forma de dosificacion que presenta propiedades de dispersion rapida, metodos de uso y procedimiento para su fabricacion.
ZA985542B (en) 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
WO1999012903A1 (en) 1997-09-09 1999-03-18 Du Pont Pharmaceuticals Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
US6277406B1 (en) 1997-10-08 2001-08-21 Fuisz Technologies Ltd. Easily processed tablet compositions
US7070936B1 (en) 1999-01-13 2006-07-04 The Research Foundation Of State University Of New York Method for designing protein kinase inhibitors
JP2001023259A (ja) 1999-07-09 2001-01-26 Sony Corp 光磁気記録媒体およびその製造方法
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
CZ2002961A3 (cs) 1999-09-17 2002-08-14 Millennium Pharmaceuticals, Inc. Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa
US6372752B1 (en) 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof
US20040039048A1 (en) 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
KR100423899B1 (ko) 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
UY26780A1 (es) 2000-06-15 2002-01-31 Pharmacia Corp Cicloalquil avb3 antagonistas
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
JP2002020362A (ja) 2000-07-06 2002-01-23 Nippon Oruganon Kk 新規ビフェニル誘導体
CA2423868C (en) 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
CA2430037A1 (en) 2000-11-20 2002-05-30 Michael S. South Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
MXPA03008888A (es) 2001-03-29 2005-03-07 Vertex Pharma Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas.
EP1402890B1 (en) 2001-06-08 2008-01-09 Institute of Medicinal Molecular Design, Inc. Sulfonamide derivatives
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
JP2003231633A (ja) 2002-02-06 2003-08-19 Tanabe Seiyaku Co Ltd 医薬組成物
JP2005517007A (ja) 2002-02-07 2005-06-09 アクシス・ファーマスーティカルズ ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
GB0209891D0 (en) 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
AU2003250701A1 (en) 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
AU2003254177A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US20040242572A1 (en) 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
EP1562911B1 (en) 2002-11-01 2010-01-06 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
ATE343583T1 (de) 2002-11-08 2006-11-15 Novo Nordisk As Halogensulfonylarylboronate
JP4896518B2 (ja) 2002-12-13 2012-03-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド ニコチンアミド系キナーゼ阻害薬
US20060100245A1 (en) 2002-12-19 2006-05-11 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues
FR2850377B1 (fr) 2003-01-23 2009-02-20 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
TWI378092B (en) 2003-06-03 2012-12-01 Rib X Pharmaceuticals Inc Biaryl heterocyclic compounds and methods of making and using the same
WO2005014532A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
KR20060073930A (ko) 2003-08-08 2006-06-29 버텍스 파마슈티칼스 인코포레이티드 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
FR2860514A1 (fr) 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
WO2005034870A2 (en) 2003-10-07 2005-04-21 Renovis, Inc. Amide compounds and ion channel ligands and uses thereof
RU2374230C2 (ru) 2003-11-05 2009-11-27 Ф.Хоффманн-Ля Рош Аг Фенильные производные в качестве ppar агонистов
WO2005063690A1 (en) 2003-12-22 2005-07-14 Merck & Co., Inc. Alpha-hydroxy amides as bradykinin antagonists or inverse agonists
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
JP4793692B2 (ja) 2004-04-26 2011-10-12 小野薬品工業株式会社 新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物
US20060135773A1 (en) 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
PL1836169T3 (pl) 2004-12-28 2012-07-31 Kinex Pharmaceuticals Llc Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
CN101253152A (zh) 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
CA2640090A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
WO2007095383A2 (en) 2006-02-15 2007-08-23 Myriad Genetics, Inc. Prodrugs
US20090076075A1 (en) 2006-03-02 2009-03-19 Frederic Henri Jung Quinoline derivatives
JP2009528335A (ja) 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キナゾリン誘導体
WO2007113565A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
US8604031B2 (en) 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors
ES2500165T3 (es) 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
JP5564251B2 (ja) * 2006-06-29 2014-07-30 キネックス ファーマシューティカルズ， エルエルシー キナーゼカスケードを調節するためのビアリール組成物および方法
EP2035372A1 (en) 2006-06-29 2009-03-18 Arena Pharmaceuticals, Inc. Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
RU2009127095A (ru) 2006-12-15 2011-01-20 Эбботт Лэборетриз (Us) Новые оксадиазольные соединения
US20100210649A1 (en) 2006-12-21 2010-08-19 Sloan-Kettering Institute For Cancer Research Pyridazinones and furan-containing compounds
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US20100256147A1 (en) 2007-04-13 2010-10-07 Hangauer Jr David G Biaryl acetamide derivatives as modulators of the kinase cascade for the treatment of hearing loss, osteoporosis and cell proliferation disorders
CN101687798B (zh) * 2007-05-17 2012-08-15 金克斯医药品有限公司 制备用于调节激酶级联的组合物的过程及其使用方法
CN107441097A (zh) 2010-04-16 2017-12-08 阿西纳斯公司 用于预防和治疗癌症的组合物以及方法
US9926273B2 (en) 2012-08-30 2018-03-27 Athenex, Inc. Composition and methods for modulating a kinase cascade

Also Published As

Publication number Publication date
US9926273B2 (en) 2018-03-27
KR20150046329A (ko) 2015-04-29
KR102346033B1 (ko) 2021-12-30
JP2015526526A (ja) 2015-09-10
US20210214305A1 (en) 2021-07-15
CA2883144C (en) 2023-01-17
US20180170875A1 (en) 2018-06-21
ES2664332T3 (es) 2018-04-19
US10106505B2 (en) 2018-10-23
CA2883144A1 (en) 2014-03-06
SI2890680T1 (en) 2018-08-31
TW201422585A (zh) 2014-06-16
CN105263907B (zh) 2018-11-20
TWI664167B (zh) 2019-07-01
US20140066445A1 (en) 2014-03-06
US20190263755A1 (en) 2019-08-29
CN105263907A (zh) 2016-01-20
HK1212329A1 (en) 2016-06-10
WO2014036426A1 (en) 2014-03-06
US20230167060A1 (en) 2023-06-01
JP6499076B2 (ja) 2019-04-10
EP2890680A1 (en) 2015-07-08
JP2019052153A (ja) 2019-04-04
HK1215544A1 (zh) 2016-09-02
JP2021006580A (ja) 2021-01-21
EP2890680B1 (en) 2018-02-28
HUE037637T2 (hu) 2018-09-28
CN109999040A (zh) 2019-07-12

Similar Documents

Publication Publication Date Title
HUE037637T2 (hu) N-(3-fluorobenzil)-2-(5-(4-morfolinofenil)piridin-2-IL) acetamid, mint fehérje tirozin kináz modulátorok
HUS2200010I1 (hu) Kondenzált heterociklusos vegyületek protein-kináz inhibitorként
HRP20190128T1 (hr) Novi spojevi kao modulatori protein kinaza
IL236495A0 (en) Heteroaromatic compounds as proton tyrosine kinase inhibitors
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
EP2833889A4 (en) PROTEIN KINASE C HEMMER AND USES THEREOF
PT3409278T (pt) Inibidores de proteína cinase heterocíclicos
EP3083559A4 (en) Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
ZA201402549B (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
IL232333A (en) N- (pyrid-4-ram) amides and n- (pyrimidin-4-ram) amides and their pharmacological and cosmetic uses
ZA201502575B (en) Heteroaromatic compounds as pi3 kinase modulators and methods of use
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
EP2870158A4 (en) PROTEIN KINASE INHIBITORS
IL237158A0 (en) Amino quinzolines as kinase inhibitors
EP2855484A4 (en) PROTEIN KINASE INHIBITORS
EP2988749A4 (en) Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
EP2895166A4 (en) AMINOISOQUINOLINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
BR112015002078A2 (pt) inibidores antibacteriais de proteína quinase
EP3082807A4 (en) Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP2822687A4 (en) ANIONIC EXCHANGE HYDROPHOBIC MIXING MODE
EP3083560A4 (en) Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
ZA201508756B (en) N-(2-fluoro-2-phenethyl)carboxamides as nematicides and endoparasiticides
EP3071572A4 (en) Protein kinase inhibitors
EP3074401A4 (en) Protein kinase inhibitors
GB201209458D0 (en) Novel compounds and their use as kinase inhibitors